Department of Pharmaceutical Sciences, Temple University School of Pharmacy , Philadelphia, Pennsylvania 19140, United States.
Department of Physics, University of Texas , Austin, Texas 78712, United States.
Mol Pharm. 2017 Sep 5;14(9):3069-3086. doi: 10.1021/acs.molpharmaceut.7b00286. Epub 2017 Jul 31.
Prediction of the rate and extent of drug absorption upon oral dosing needs models that capture the complexities of both the drug molecule and intestinal physiology. We report here the development of a continuous intestinal absorption model based on the convection-diffusion equation. The model includes explicit enterocyte apical membrane and intracellular lipid radial compartments along the length of the intestine. Physiologic functions along length x are built into the model and include velocity, diffusion, surface areas, and pH of the intestine. Also included are expression levels of the intestinal active uptake transporter OATP2B1 and efflux transporter P-gp. Oral dosing of solution as well as solid (with a dissolution function) was modeled for several drugs. The fraction absorbed (FA) and concentration-time (C-t) profiles were predicted and compared with clinical data. Overall, FA was well predicted upon oral (n = 21) or colonic dosing (n = 11), with four outliers. The overall accuracy (prediction of the correct bin) was 81% with outliers and 90% without outliers. Of the nine solution dosing data sets, six drugs were very well predicted with an exposure overlap coefficient (EOC) > 0.9 and predicted C and T values similar to those observed. Of the six solid dose formulations evaluated, the EOC values were > 0.9 for all drugs except budesonide. The observed precipitation of nifedipine at high doses was predicted by the model. Most of the poor predictions were for drugs that are known to be transporter substrates. As proof of concept, incorporating OATP2B1 and P-gp markedly improved the EOC and predicted C and T for fexofenadine. Finally, the continuous intestinal model accurately recapitulated the known relationships between drug absorption and permeability, solubility, and particle size. Together, these results indicate that this preliminary intestinal absorption model offers a simple and straightforward framework to build in complexities such as drug permeability, lipid partitioning, solubility, metabolism, and transport for improved prediction of the rate and extent of drug absorption.
口服给药时药物吸收的速度和程度需要能够捕捉药物分子和肠道生理学复杂性的模型。我们在此报告了一种基于对流-扩散方程的连续肠道吸收模型的开发。该模型包括沿肠道长度的明确的肠细胞顶膜和细胞内脂质径向隔室。生理功能沿着 x 长度构建到模型中,包括肠道的速度、扩散、表面积和 pH。还包括肠道主动摄取转运体 OATP2B1 和外排转运体 P-gp 的表达水平。对几种药物进行了溶液和固体(带有溶解功能)的口服给药建模。预测了吸收分数(FA)和浓度-时间(C-t)曲线,并将其与临床数据进行比较。总体而言,口服(n=21)或结肠给药(n=11)的 FA 得到了很好的预测,有四个离群值。有离群值时的总体准确性(正确分类的预测)为 81%,无离群值时为 90%。在 9 个溶液给药数据集,有 6 种药物的预测非常好,暴露重叠系数(EOC)>0.9,预测的 C 和 T 值与观察值相似。在评估的 6 种固体剂量配方中,除了布地奈德外,所有药物的 EOC 值都>0.9。模型预测了硝苯地平在高剂量下的沉淀。大多数预测不佳的药物是已知的转运体底物。作为概念验证,纳入 OATP2B1 和 P-gp 显著提高了依匹斯汀的 EOC 以及预测的 C 和 T。最后,连续肠道模型准确地再现了药物吸收与通透性、溶解度和粒径之间的已知关系。这些结果表明,这种初步的肠道吸收模型为提高药物吸收速度和程度的预测提供了一个简单而直接的框架,可以构建药物通透性、脂质分配、溶解度、代谢和转运等复杂性。